Profile picture of 谢文荪

谢文荪医生

Profile picture of 谢文荪

理学士 (美国)、医学博士 (美国)、内科学 (美国)、肿瘤内科学 (美国)、美国内科医学委员会内科和肿瘤内科院士(美国)

肿瘤内科医生
安微尼亚山(Mount Alvernia)

“我热爱肿瘤治疗的事业,因为它提供了以多种不同方式帮助患者的机会。”

Biography

介绍

谢文荪医生专门研究各种类型的癌症,并积极开发新型癌症诊断方法和分子靶向抗癌治疗方法。在凭借罗德奖学金在牛津大学学习哲学和心理学之后,谢医生从约翰·霍普金斯大学获得了医学学位。在完成杜克大学的内科医学和约翰·霍普金斯大学的肿瘤内科学培训后,谢医生在约翰·霍普金斯大学医学院担任全职教职人员,积极从事患者治疗、教学和研究工作,主要任职于血液系统恶性肿瘤学部门。他仍然担任约翰·霍普金斯大学的兼职助理教授,并且是新加坡国立大学新加坡癌症科学研究所的副首席研究员,积极从事开发癌症诊断治疗新的检测和治疗方法。

谢医生对分子靶向癌症治疗、免疫治疗和分子诊断学有着浓厚的研究兴趣,已经建立了多个国际研究项目,涉及新加坡、香港、韩国、菲律宾、缅甸和美国的研究中心,主要研究淋巴瘤、鼻咽癌和肝癌的新治疗方法和新诊断检查方法。他还是三十多个已完成或正在进行的临床试验的主要研究者,这些试验研究多种癌症的新治疗方法。谢医生共撰写了 80 多篇科学文章、摘要和书籍章节,并在地区和国际医学与科学会议上发表演讲。谢医生致力于为目前的癌症患者提供循证治疗,并开发更有效的癌症治疗方法。

谢医生接受所有癌症类型的转诊,特别关注淋巴瘤、头颈部肿瘤、肺癌以及肝胆癌。

查看印尼语版本
查看越南语版本

Research

发表文章

  • Cytidine Methylation of Regulatory Sequences Near the Pi-Class Glutathione S-Transferase Gene Accompanies Human Prostatic Carcinogenesis. Lee, W.H, Morton, R.A, Epstein, J.I., Brooks, J.D., Campbell, P.A., Bova, G.S., Hsieh, W.S., Isaacs, W.B., and Nelson, W.G. Natl.Acad. Sci. 1994; 91 (24): 11733-11737.

  • Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer. Hsieh, WS, Soo, RA, Peh, BK, Loh, T, Dong, DF, Soh, D, Wong, LS, Green, SR, Chiao, JT, Cui, CY, Lai, YF, Lee, SC, Mow, B, Soong, R., Salto-Tellez, M, Goh, BC. Clinical Cancer Research 2019; 15(4): 1435-42.

  • A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Low, SW, Tao, Q*, Ng, KM, Goh, HK, Shu, XS, Ambinder, RF, Srivastava, G,  Shamay, M, Chan ATC, Popescu, NC, Hsieh, WS*. Oncogene 2011; 30(16): 1923-1935. *Co-Corresponding Author.

  • Plasma Epstein-Barr virus DNA as a marker of tumor response in Hodgkin lymphoma. Kanakry, JA, Li, HL, Gellert, LL, Lemas, MV, Hsieh, WS, Hong, FX, Tan, KL, Gascoyne, RD, Gordon, LI, Fisher, RI, Bartlett, NL, Stiff, P, Cheson, BD, Advani, R, Miller, TP, Kahl, BS, Horning, SJ, Ambinder, RF. Blood 2013; 121 (18): 3547-3553.

  • A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, Poon RT, Yeo WM, Park JW, Tay MH, Hsieh WS, Kappeler C, Rajagopalan P, Krissel H, Jeffers M, Yen CJ, Tak WY.  Clinical Cancer Research 2014; 20 (23): 5976-5985.

“我热爱肿瘤治疗的事业,因为它提供了以多种不同方式帮助患者的机会。”

Languages spoken

  • Mandarin
  • 英语

媒体

所属机构和会员关系

  • 美国癌症研究协会 (AACR) 成员
  • 国家医疗保健小组副主席,行业专业审查委员会 B1
  • 约翰霍普金斯大学医学院兼职助理教授
  • 新加坡国立大学新加坡癌症科学研究所执行理事

发表文章

  • Cytidine Methylation of Regulatory Sequences Near the Pi-Class Glutathione S-Transferase Gene Accompanies Human Prostatic Carcinogenesis. Lee, W.H, Morton, R.A, Epstein, J.I., Brooks, J.D., Campbell, P.A., Bova, G.S., Hsieh, W.S., Isaacs, W.B., and Nelson, W.G. Natl.Acad. Sci. 1994; 91 (24): 11733-11737.

  • Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer. Hsieh, WS, Soo, RA, Peh, BK, Loh, T, Dong, DF, Soh, D, Wong, LS, Green, SR, Chiao, JT, Cui, CY, Lai, YF, Lee, SC, Mow, B, Soong, R., Salto-Tellez, M, Goh, BC. Clinical Cancer Research 2019; 15(4): 1435-42.

  • A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Low, SW, Tao, Q*, Ng, KM, Goh, HK, Shu, XS, Ambinder, RF, Srivastava, G,  Shamay, M, Chan ATC, Popescu, NC, Hsieh, WS*. Oncogene 2011; 30(16): 1923-1935. *Co-Corresponding Author.

  • Plasma Epstein-Barr virus DNA as a marker of tumor response in Hodgkin lymphoma. Kanakry, JA, Li, HL, Gellert, LL, Lemas, MV, Hsieh, WS, Hong, FX, Tan, KL, Gascoyne, RD, Gordon, LI, Fisher, RI, Bartlett, NL, Stiff, P, Cheson, BD, Advani, R, Miller, TP, Kahl, BS, Horning, SJ, Ambinder, RF. Blood 2013; 121 (18): 3547-3553.

  • A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, Poon RT, Yeo WM, Park JW, Tay MH, Hsieh WS, Kappeler C, Rajagopalan P, Krissel H, Jeffers M, Yen CJ, Tak WY.  Clinical Cancer Research 2014; 20 (23): 5976-5985.

搜索

Make an appointment